Recent structural data support the idea that GPCRs, despite their small size, are sophisticated allosteric machines with multiple signaling outputs. You have full access to this article via your ...
Septerna aims to find drugs that modulate GPCRs via allosteric sites, testing the approach across endocrine, CNS, inflammatory and metabolic diseases. Septerna has raised nearly US$500 million ...
GPCRs are a fertile source of drug targets ... Septerna is also developing SEP-631, billed as an MRGPRX2 negative allosteric modulator for the treatment of chronic spontaneous urticaria (CSU ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback